[1]
Kassebaum NJ, Arora M, Barber RM, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388(10053): 1603-58.
[http://dx.doi.org/10.1016/S0140-6736(16)31460-X] [PMID: 27733283]
[http://dx.doi.org/10.1016/S0140-6736(16)31460-X] [PMID: 27733283]
[2]
So A, Dumusc A, Nasi S. The role of IL-1 in gout: From bench to bedside. Rheumatology (Oxford) 2018; 57 (Suppl. 1): i12-9.
[PMID: 29272514]
[PMID: 29272514]
[3]
ter Borg EJ, Rasker JJ. Gout in the elderly, a separate entity? Ann Rheum Dis 1987; 46(1): 72-6.
[http://dx.doi.org/10.1136/ard.46.1.72] [PMID: 3813677]
[http://dx.doi.org/10.1136/ard.46.1.72] [PMID: 3813677]
[4]
Jansen TL, Rasker JJ. Crystal -induced arthritis, a review for clinicians. Clin Exp Rheumatol 2011; 29(6): 1032-9.
[PMID: 22133072]
[PMID: 22133072]
[5]
Darmawan J, Rasker JJ, Nuralim H. The effect of control and self-medication of chronic gout in a developing country. Outcome after 10 years. J Rheumatol 2003; 30(11): 2437-43.
[PMID: 14677190]
[PMID: 14677190]
[6]
Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64(10): 1431-46.
[http://dx.doi.org/10.1002/acr.21772] [PMID: 23024028]
[http://dx.doi.org/10.1002/acr.21772] [PMID: 23024028]
[7]
Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76(1): 29-42.
[http://dx.doi.org/10.1136/annrheumdis-2016-209707] [PMID: 27457514]
[http://dx.doi.org/10.1136/annrheumdis-2016-209707] [PMID: 27457514]
[8]
Kiltz U, Smolen J, Bardin T, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis 2017; 76(4): 632-8.
[http://dx.doi.org/10.1136/annrheumdis-2016-209467] [PMID: 27658678]
[http://dx.doi.org/10.1136/annrheumdis-2016-209467] [PMID: 27658678]
[9]
FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American college of rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken) 2020; 72(6): 744-60.
[http://dx.doi.org/10.1002/acr.24180] [PMID: 32391934]
[http://dx.doi.org/10.1002/acr.24180] [PMID: 32391934]
[10]
Reinders MK, Haagsma C, Jansen TL, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009; 68(6): 892-7.
[http://dx.doi.org/10.1136/ard.2008.091462] [PMID: 18633127]
[http://dx.doi.org/10.1136/ard.2008.091462] [PMID: 18633127]
[11]
Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: Investigating the cause and minimizing the risk. Nat Rev Rheumatol 2016; 12(4): 235-42.
[http://dx.doi.org/10.1038/nrrheum.2015.132] [PMID: 26416594]
[http://dx.doi.org/10.1038/nrrheum.2015.132] [PMID: 26416594]
[12]
Jansen TL, Reinders MK, van Roon EN, Brouwers JR. Benzbromarone withdrawn from the European market: Another case of “absence of evidence is evidence of absence”? Clin Exp Rheumatol 2004; 22(5): 651.
[PMID: 15485024]
[PMID: 15485024]
[13]
Reinders MK, van Roon EN, Jansen TL, et al. Efficacy and tolerability of urate-lowering drugs in gout: A randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009; 68(1): 51-6.
[http://dx.doi.org/10.1136/ard.2007.083071] [PMID: 18250112]
[http://dx.doi.org/10.1136/ard.2007.083071] [PMID: 18250112]
[14]
Reinders MK, van Roon EN, Houtman PM, Brouwers JR, Jansen TL. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 2007; 26(9): 1459-65.
[http://dx.doi.org/10.1007/s10067-006-0528-3] [PMID: 17308859]
[http://dx.doi.org/10.1007/s10067-006-0528-3] [PMID: 17308859]
[15]
Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: Current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis 2016; 8(4): 145-59.
[http://dx.doi.org/10.1177/1759720X16646703] [PMID: 27493693]
[http://dx.doi.org/10.1177/1759720X16646703] [PMID: 27493693]
[16]
Jansen TL, Perez-Ruiz F, Tausche AK, Richette P. International position paper on the appropriate use of uricosurics with the introduction of lesinurad. Clin Rheumatol 2018; 37(12): 3159-65.
[http://dx.doi.org/10.1007/s10067-018-4306-9] [PMID: 30244431]
[http://dx.doi.org/10.1007/s10067-018-4306-9] [PMID: 30244431]
[17]
Tausche AK, Alten R, Dalbeth N, et al. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: A 6 month phase 3 clinical trial and extension study. Rheumatology (Oxford) 2017; 56(12): 2170-8.
[http://dx.doi.org/10.1093/rheumatology/kex350] [PMID: 29029210]
[http://dx.doi.org/10.1093/rheumatology/kex350] [PMID: 29029210]
[18]
Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: Randomized, double-blind, placebo-controlled study in gout subjects with inadequate response to standard of care allopurinol (a US-based Study). Arthritis Rheumatol 2017; 69(1): 203-12.
[http://dx.doi.org/10.1002/art.39840] [PMID: 27564409]
[http://dx.doi.org/10.1002/art.39840] [PMID: 27564409]
[19]
Bardin T, Keenan RT, Khanna PP, et al. Lesinurad in combination with allopurinol: A randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis 2017; 76(5): 811-20.
[http://dx.doi.org/10.1136/annrheumdis-2016-209213] [PMID: 27821644]
[http://dx.doi.org/10.1136/annrheumdis-2016-209213] [PMID: 27821644]
[20]
Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a Selective uric acid reabsorption inhibitor, in combination with febuoxstat in patients with tophaceous gout: Findings of a Phase III Clinical Trial. Arthritis Rheumatol 2017; 69(9): 1903-13.
[http://dx.doi.org/10.1002/art.40159] [PMID: 28597604]
[http://dx.doi.org/10.1002/art.40159] [PMID: 28597604]
[21]
Singh JA. Lesinurad combination therapy with allopurinol in gout: Do clear studies make the treatment of gout clearer? Ann Rheum Dis 2017; 76(5): 779-81.
[http://dx.doi.org/10.1136/annrheumdis-2016-210519] [PMID: 28039184]
[http://dx.doi.org/10.1136/annrheumdis-2016-210519] [PMID: 28039184]
[22]
Dalbeth N, Jones G, Terkeltaub R, et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: Crystal extension study. Arthritis Res Ther 2019; 21(1): 8.
[http://dx.doi.org/10.1186/s13075-018-1788-4] [PMID: 30616614]
[http://dx.doi.org/10.1186/s13075-018-1788-4] [PMID: 30616614]
[23]
Lesinurad - AstraZeneca. Available from: https://adisinsight.springer.com/drugs/800028980 (Accessed on August, 2021).
[24]
Tan PK, Liu S, Gunic E, Miner JN. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. Sci Rep 2017; 7(1): 665.
[http://dx.doi.org/10.1038/s41598-017-00706-7] [PMID: 28386072]
[http://dx.doi.org/10.1038/s41598-017-00706-7] [PMID: 28386072]
[25]
Fitz-Patrick D, Roberson K, Niwa K, et al. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials. Mod Rheumatol 2019; 29(6): 1042-52.
[http://dx.doi.org/10.1080/14397595.2018.1538003] [PMID: 30334639]
[http://dx.doi.org/10.1080/14397595.2018.1538003] [PMID: 30334639]
[26]
Stack AG, Dronamraju N, Parkinson J, et al. Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: A randomized trial. Am J Kidney Dis 2021; 77(4): 481-9.
[http://dx.doi.org/10.1053/j.ajkd.2020.09.009] [PMID: 33130235]
[http://dx.doi.org/10.1053/j.ajkd.2020.09.009] [PMID: 33130235]
[27]
Stack AG, Han D, Goldwater R, et al. Dapagliflozin added to verinurad plus febuxostat further reduces serum uric acid in hyperuricemia: The quartz study. J Clin Endocrinol Metab 2021; 106(5): e2347-56.
[http://dx.doi.org/10.1210/clinem/dgaa748] [PMID: 33075806]
[http://dx.doi.org/10.1210/clinem/dgaa748] [PMID: 33075806]
[28]
Iqbal A, Iqbal K, Farid E, et al. Efficacy and safety of dotinurad in hyperuricemic patients with or without gout: A systematic review and meta-analysis of randomized controlled trials. Cureus 2021; 13(4)e14428
[http://dx.doi.org/10.7759/cureus.14428] [PMID: 33996294]
[http://dx.doi.org/10.7759/cureus.14428] [PMID: 33996294]
[29]
Takahashi T, Beppu T, Hidaka Y, Hosoya T. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: A pooled analysis of individual participant data in phase II and III trials. Clin Exp Hypertens 2021; 43(8): 730-41.
[http://dx.doi.org/10.1080/10641963.2021.1950752] [PMID: 34425059]
[http://dx.doi.org/10.1080/10641963.2021.1950752] [PMID: 34425059]
[30]
Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: Randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. Clin Exp Nephrol 2020; 24(S1) (Suppl. 1): 53-61.
[http://dx.doi.org/10.1007/s10157-019-01818-2] [PMID: 31792640]
[http://dx.doi.org/10.1007/s10157-019-01818-2] [PMID: 31792640]
[31]
Azevedo VF, Kos IA, Vargas-Santos AB, da Rocha Castelar Pinheiro G, Dos Santos Paiva E. Benzbromarone in the treatment of gout. Adv Rheumatol 2019; 59(1): 37.
[http://dx.doi.org/10.1186/s42358-019-0080-x] [PMID: 31391099]
[http://dx.doi.org/10.1186/s42358-019-0080-x] [PMID: 31391099]
[32]
Burns CM, Wortmann RL. Latest evidence on gout management: What the clinician needs to know. Ther Adv Chronic Dis 2012; 3(6): 271-86.
[http://dx.doi.org/10.1177/2040622312462056] [PMID: 23342241]
[http://dx.doi.org/10.1177/2040622312462056] [PMID: 23342241]
[33]
Jordan K, Jeffries A. Current treatment options for acute and chronic gout. Prescriber 2014; 5(17): 25-34.
[http://dx.doi.org/10.1002/psb.1238]
[http://dx.doi.org/10.1002/psb.1238]
[34]
Klein RW, Kabadi S, Cinfio FN, Bly CA, Taylor DCA, Szymanski KA. Budget impact of adding lesinurad for second-line treatment of gout: A US health plan perspective. J Comp Eff Res 2018; 7(8): 807-16.
[http://dx.doi.org/10.2217/cer-2017-0103] [PMID: 29792516]
[http://dx.doi.org/10.2217/cer-2017-0103] [PMID: 29792516]
[36]
White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018; 378(13): 1200-10.
[http://dx.doi.org/10.1056/NEJMoa1710895] [PMID: 29527974]
[http://dx.doi.org/10.1056/NEJMoa1710895] [PMID: 29527974]
[37]
Cuenca JA, Balda J, Palacio A, Young L, Pillinger MH, Tamariz L. Febuxostat and cardiovascular events: A systematic review and meta-analysis. Int J Rheumatol 2019; 20191076189
[http://dx.doi.org/10.1155/2019/1076189] [PMID: 30863448]
[http://dx.doi.org/10.1155/2019/1076189] [PMID: 30863448]
[38]
Liang N, Sun M, Sun R, et al. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: A prospective, randomized controlled study in a Chinese primary gout cohort. Arthritis Res Ther 2019; 21(1): 200.
[http://dx.doi.org/10.1186/s13075-019-1976-x] [PMID: 31477161]
[http://dx.doi.org/10.1186/s13075-019-1976-x] [PMID: 31477161]
Article Metrics
33
2
